Alzamend Neuro Files S-1/A Amendment
Ticker: ALZN · Form: S-1/A · Filed: Jul 3, 2024 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | S-1/A |
| Filed Date | Jul 3, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.0001, $0.396, $35 million, $2.5 million, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, registration, amendment
TL;DR
Alzamend Neuro filed an S-1/A amendment on July 3rd. Still working through SEC stuff.
AI Summary
Alzamend Neuro, Inc. filed an S-1/A amendment on July 3, 2024, to its registration statement. The company, incorporated in Delaware, is in the pharmaceutical preparations industry and is headquartered in Atlanta, GA. This filing is an amendment to their existing registration, indicating ongoing efforts to comply with SEC regulations for public offerings or existing securities.
Why It Matters
This filing indicates Alzamend Neuro is actively updating its registration statement with the SEC, which is a necessary step for companies undergoing public offerings or other securities-related regulatory processes.
Risk Assessment
Risk Level: medium — S-1/A filings often relate to capital raises or significant corporate actions, which inherently carry risks for investors.
Key Numbers
- 333-279920 — SEC Registration Number (Identifies the specific registration statement being amended.)
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- July 3, 2024 (date) — Filing Date
- 333-279920 (registration_number) — SEC Registration Number
- Stephan Jackman (person) — Chief Executive Officer
- Henry Nisser (person) — Executive Vice President and General Counsel
FAQ
What is the purpose of this S-1/A filing?
This filing is Amendment No. 2 to the Form S-1 Registration Statement, indicating updates or changes to the original registration filed with the SEC.
When was this amendment filed?
The amendment was filed on July 3, 2024.
What is Alzamend Neuro, Inc.'s primary business?
Alzamend Neuro, Inc. is classified under Pharmaceutical Preparations (SIC Code 2834).
Where is Alzamend Neuro, Inc. headquartered?
The company's principal executive offices are located at 3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA 30326.
Who are the key executives mentioned in the filing?
Stephan Jackman is listed as Chief Executive Officer, and Henry Nisser is listed as Executive Vice President and General Counsel.
Filing Stats: 4,569 words · 18 min read · ~15 pages · Grade level 16.6 · Accepted 2024-07-03 16:31:07
Key Financial Figures
- $0.0001 — 0,000 shares of common stock, par value $0.0001 per share (the "Common Stock"), of Alza
- $0.396 — orted by The Nasdaq Capital Market, was $0.396 per share. We are a "smaller reportin
- $35 million — LS") for our Common Stock was below the $35 million minimum MVLS requirement for continued
- $2.5 million — requires stockholder equity of at least $2.5 million (or an alternative listing standard), a
- $1.00 — e for the Common Stock had closed below $1.00 per share for the previous 30 consecuti
Filing Documents
- z72242s1a2.htm (S-1/A) — 322KB
- alzamendlogo_med.jpg (GRAPHIC) — 24KB
- 0001214659-24-011977.txt ( ) — 356KB
RISK FACTORS
RISK FACTORS 5 PRIVATE PLACEMENT 8
DESCRIPTION OF SECURITIES BEING OFFERED
DESCRIPTION OF SECURITIES BEING OFFERED 12 SELLING STOCKHOLDER 13 PLAN OF DISTRIBUTION 14
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 15 LEGAL MATTERS 20 EXPERTS 20 INFORMATION INCORPORATED BY REFERENCE 20 WHERE YOU CAN FIND MORE INFORMATION 21 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the SEC. The Selling Stockholder may, from time to time, sell up to 125,000,000 shares of our Common Stock, as described in this prospectus. We will not receive any proceeds from the sale by the Selling Stockholder of the securities described in this prospectus, provided, that we would receive certain proceeds in the event that the Selling Stockholder elects to exercise its Warrants. You should rely only on the information contained in this prospectus, any supplement to this prospectus or in any free writing prospectus, filed with the SEC. Neither we nor the Selling Stockholder have authorized anyone to provide you with additional information or information different from that contained in this prospectus, or any applicable prospectus supplement or any free writing prospectuses prepared by us or on our behalf and filed with the SEC. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The Selling Stockholder is offering to sell our securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to the offering. The prospectus supplement or post-effective amendment, as the case may be, may add, update or change information contained in this prospectus with respect t